Pioglitazone HCl

Catalog No.S2046 Synonyms: AD-4833, U-72107E

For research use only.

Pioglitazone HCl (AD-4833, U-72107E) is an inhibitor of cytochrome P450 (CYP)2C8 and CYP3A4 enzymes. Pioglitazone HCl inhibits CYP2C8, CYP3A4 and CYP2C9 with Ki of 1.7 μM, 11.8 μM and 32.1 μM, respectively. Pioglitazone HCl is also a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist with EC50 of 0.93 μM and 0.99 μM for human PPARγ and mouse PPARγ, respectively. Pioglitazone HCl inhibits mitochondrial iron uptake, lipid peroxidation, and subsequent ferroptosis.

Pioglitazone HCl Chemical Structure

CAS No. 112529-15-4

Selleck's Pioglitazone HCl has been cited by 5 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective P450 (e.g. CYP17) Inhibitors

Other P450 (e.g. CYP17) Products

Biological Activity

Description Pioglitazone HCl (AD-4833, U-72107E) is an inhibitor of cytochrome P450 (CYP)2C8 and CYP3A4 enzymes. Pioglitazone HCl inhibits CYP2C8, CYP3A4 and CYP2C9 with Ki of 1.7 μM, 11.8 μM and 32.1 μM, respectively. Pioglitazone HCl is also a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist with EC50 of 0.93 μM and 0.99 μM for human PPARγ and mouse PPARγ, respectively. Pioglitazone HCl inhibits mitochondrial iron uptake, lipid peroxidation, and subsequent ferroptosis.
Targets
Ferroptosis [8]
()
hPPARγ [1]
(Cell-free assay)
rPPARγ [6]
(Cell-free assay)
CYP2C8 [7]
(Cell-free assay)
CYP3A4 [7]
(Cell-free assay)
Click to View More Targets
0.93 μM(EC50) 0.99 μM(EC50) 1.7 μM(Ki) 11.8 μM(Ki)
In vitro

Pioglitazone inhibits LPS-induced iNOS expression and NO generation, and inhibition of iNOS is sufficient to protect dopaminergic neurons against LPS insult. Pioglitazone protects dopaminergic neurons against LPS insult at least via inhibiting iNOS expression and NO generation, which is potentially mediated via inhibition of p38 MAPK activity. Pioglitazone inhibits LPS-induced phosphorylation of p38 MAPK. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
COS cells MkfMSpVv[3Srb36gZZN{[Xl? MorzWJJidnOlcnnweIlwdmGuIHHjeIl3[XSrb36gbY4hS0:VIHPlcIx{KGW6cILld5NqdmdiUGDBVkBo[W2vYTDhcoQhWliUIHHsdIhiQyC4YXz1[ZMhcW5idHjlJJBiemWwdHjld4V{KGmwZHnjZZRmeyB7NTWgZ49v\mmmZX7j[UBqdnSnco\hcEwhTUN3ME2wMlQ6KM7:TR?= NYHHdmg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG5NFYzQTNpPkGxPVA3Ojl|PD;hQi=>
HepG2 cells NV\H[Zd4TnWwY4Tpc44h[XO|YYm= M3PLcHBmem:6aYPvcYUheHKxbHnm[ZJifG:{IHHjeIl3[XSnZDDy[YNmeHSxcjDnZY1u[SCjZ3;ubZN1cWNiYXP0bZZqfHliaX6gTIVxTzJiY3XscJMtKEWFNUC9O{43KM7:TR?= MoWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB5MUS1NFMoRjFyN{G0OVA{RC:jPh?=
CV-1 M3HqVmZ2dmO2aX;uJIF{e2G7 Mk\tTY4hfmm2cn:geJJidnOlcnnweIlwdmGuIHHjeIl3[XSrb36gc4YhWGW{b4jpd49u\SCycn;sbYZmemG2b4KgZYN1cX[jdHXkJJJm[2WydH;yJIdidW2jIDjQVGFTMSCneIDy[ZN{\WRiaX6gR3YuOSClZXzsd{whTUN3ME2wMlY6|ryPLh?= NEHacmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi96NUe2PVA4Lz56NUe2PVA4RC:jPh?=
3T3-L1 Mn3kSpVv[3Srb36gZZN{[Xl? MXfF[oZm[3SrdnWgZ49v[2WwdILheIlwdiCob4KgOVAmKGWwaHHuZ4Vu\W62IH;mJIlve3WuaX6tbY5lfWOnZDD0dolodHmlZYLp[IUh[WOldX31cIF1cW:wIHnuJFNVOy2OMTDj[YxteyxiRVO1NF0xNjF4zszNMi=> Mnr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTV7OUK0NUc,QTV7OUK0NVww[T5?
CV-1 MXLGeY5kfGmxbjDhd5NigQ>? Mn;HRYN1cX[jdHnvckBw\iCyZYLvfIl{d22nIIDyc4xq\mW{YYTvdkBi[3SrdnH0[YQhemWlZYD0c5Ih\2GvbXGgcYVie3W{ZXSgZpkhcW6mdXP0bY9vKG:oIEWwKUBw\iCvYYjpcZVuKGGua3HsbY5mKHCqb4PwbIF1[XOnIHHjeIl3cXS7LDD0doFve2[nY4Tpc44h[XO|YYmgbY4hS1ZvMTDj[YxteyxiRVO1NF0xNjV6OEi0{txONg>? NFXV[XM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OEO2OlIxLz57OEO2OlIxRC:jPh?=
CV-1 M1XmN2Z2dmO2aX;uJIF{e2G7 NFvvZVhO[XirbXHsJJJmeG:{dHXyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUHXyc5hqe2:vZTDwdo9tcW[ncnH0c5Ih[WO2aY\heIVlKHKnY3XweI9zKGejbX3hJGdidDRiY3jpcYVzcWNiaX6geJJidnOrZX70cJkhfHKjboPm[YN1\WRiQ2[tNUBk\WyuczDifUBnfW6ldHnvcoFtKGG|c3H5MEBGSzVyPUCuOVjPxE1w MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTd{MEi1OEc,OTF5MkC4OVQ9N2F-
HEK293 MYHGeY5kfGmxbjDhd5NigQ>? NFfIZnVC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBz\WOncITvdkBqdnSncnHjeIlwdiC5aYToJJN1\XKxaXSgdoVk\XC2b4KgZ49i[3SrdnH0c5IuOSCkeTDFXWZRKGKjc3XkJJJmeG:{dHXyJIdmdmViYYPzZZk> NVvoWFh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[2PFAyPTlpPkG2OlgxOTV7PD;hQi=>
HEK293 MkX0SpVv[3Srb36gZZN{[Xl? NHnaWmZC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBz\WOncITvdkBqdnSncnHjeIlwdiC5aYToJJJmfGmwb3nkJHguemWlZYD0c5Ih[WyyaHGgZpkhTVmIUDDiZZNm\CC{ZYDvdpRmeiCpZX7lJIF{e2G7 NUDldFhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[2PFAyPTlpPkG2OlgxOTV7PD;hQi=>
CV1 MlL0SpVv[3Srb36gZZN{[Xl? NXHEUGluXHKjboPhZ5RqfmG2aX;uJI9nKFCSQWLnZY1u[SCrbjDDWlEh[2WubIOsJGVEPTB;MD61Oe69VS5? NGn4ZpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkiyNVc3QSd-MU[4NlE4Pjl:L3G+
Cos7 MofkSpVv[3Srb36gZZN{[Xl? NVf6NYRkOTRiaILz NIHiUo9VemGwc3HjeIl3[XSrb36gc4YhcHWvYX6gVHBCWmejbX3hJGxDTCCneIDy[ZN{\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS2:|NzDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIH\1d4VlKEeDTEStSGJFKGGodHXyJFE1KGi{czDifUBFfWGuLVfsc{BNfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5|zszNMi=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODNyN{m4NUc,OjB|MEe5PFE9N2F-
3T3L1 NXrPNpNpTnWwY4Tpc44h[XO|YYm= M1PXU|ExOCC3bX;sM2w> NH\WdYJKdmO{ZXHz[UBqdiCSUFHS[4FudWFibWLORUBt\X[nbIOgbY4hdW:3c3WgN3Q{VDFiY3XscJMh[XRiMUCwJJVud2xxTDDifUBTXC2SQ2K= NGn5WGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO5NlY1PSd-MkCzPVI3PDV:L3G+
CHO NYf5OVFNTnWwY4Tpc44h[XO|YYm= NWXnU2JXSWO2aY\heIlwdiCxZjDHZYw1NXSjZ3fl[EBpfW2jbjDQVGFT\2GvbXGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4yPM7:TT6= M3vnVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkW2OFk1Lz5{ME[1OlQ6PDxxYU6=
HEK293T NEnlR4hHfW6ldHnvckBie3OjeR?= NGHCR4gyKHWP NYmyclF1OjRiaILz NVrXSYNUWGG{dHnhcEBi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZU1NSkRiZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKHKnY3XweI9zKHS{YX7zZYN1cX[jdHnvckBifCBzIIXNJIFnfGW{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> NEjYemY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUCzNFI3Oyd-MkGwN|AzPjN:L3G+
COS-1 M{fG[mZ2dmO2aX;uJIF{e2G7 NUPWTFFNSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBEV1NvMTDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuN|nPxE1w Mkn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{C2OFkoRjJzMUOwOlQ6RC:jPh?=
CHO NHjhZpFHfW6ldHnvckBie3OjeR?= MYqyOEBpenN? NFrscJdR[XK2aXHsJIFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDHZYw1NXKnc4DvcpNqfmVibIXjbYZmemG|ZTDy[ZBwenSncjDwcIF{dWmmIHHmeIVzKDJ2IHjyd{BjgSC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTB;MD6zPe69VS5? NHqzVJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3O|g4PSd-MkGzO|c5PzV:L3G+
COS7 MUHGeY5kfGmxbjDhd5NigQ>? M2G2Tm1w\HWuYYTpc44hd2ZiaIXtZY4hWFCDUnfhcY1iNUyERDDlfJBz\XO|ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliQ1;TO{Bk\WyuczDjc{11emGwc3\lZ5Rm\CC5aYToJGdidDRiYYPz[ZN{\WRiYYOgZYN1cX[jdHnvckBw\iC2cnHud4FkfGm4YYTpc44h[WO2aY\peJkh[nlibIXjbYZmemG|ZTDhd5NigSxiRVO1NF0xNjQQvF2u NX\iXpVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4O|MxPzBpPkKxPFc{ODdyPD;hQi=>
Sf21 M1LifmZ2dmO2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJGJUTVBiZYjwdoV{e2WmIHnuJJBt[XOvYTDt[Y1jemGwZTD2[ZNq[2ynczDv[kBU\jJzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSVSSLXTldIVv\GWwdDDbN2hefGG3cn;jbI9t[XSnIIXweIFs\SxiSVO1NF0xNjQQvF2u M1\hPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[1OlI{Lz5{MUm2OVYzOzxxYU6=
Sf21 MnHkSpVv[3Srb36gZZN{[Xl? NYfEbZFNUW6qaXLpeIlwdiCxZjDTdJJi\3WnLVThe4xmgSC{YYSgRpNmeCCneIDy[ZN{\WRiaX6gdIxie22jIH3lcYJz[W6nII\ld4lkdGW|IH;mJHNnOjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBCXFBvZHXw[Y5l\W62IGuzTH11[XW{b3Poc4xifGVidYD0ZYtmNCCLQ{WwQVLPxE1w MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4NU[yN{c,OjF7NkW2NlM9N2F-
HepG2 NHfkR2NHfW6ldHnvckBie3OjeR?= NHfQTHUzOCCqcoO= Mnn5RYdwdmm|dDDhZ5Rqfmm2eTDheEBISUx2LYTh[4dm\CCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczD0doFve2GldHn2ZZRqd25iYX\0[ZIhOjBiaILzJIJ6KGKndHGt[4Ft[WO2b4Pp[IF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwNUhOwG0v M3O1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{SxOVc{Lz5{MkO0NVU4OzxxYU6=
HEK293 NHPVdohHfW6ldHnvckBie3OjeR?= MV[xPEBpenN? MWnUdoFve2GldHn2ZZRqd25ib3[gbJVu[W5iR1HMOE1nfXOnZDDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKHS{YX7z[oVkfGWmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAyQCCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE45|ryPLh?= NF3pZoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{GwNlg6OSd-MkOxNFI5QTF:L3G+
COS7 M3nuSmZ2dmO2aX;uJIF{e2G7 MkK1WJJidnOjY4TpeoF1cW:wIH;mJGdCVDRvZoXz[YQhcHWvYX6gVHBCWmejbX3hJIxq\2GwZDDibY5lcW6pIHTvcYFqdiC2cnHud4Zm[3SnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjMQvF2u NV;wd2FoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxN|A6PjRpPkKzNVMxQTZ2PD;hQi=>
THP1 MlzoRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? M4DuSFEhcHJ? NWTPV2xrSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCqdX3hckBVUFBzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWE2DLXnu[JVk\WRiTVPQMVEhe2WlcnX0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOSCqcjDwdolweiCSTVGtZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IES4JIhzeyCkeTDFUGlUSSxiSVO1NF0yQC56NN88UU4> NETMVGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ixNVA6Oid-MkO4NVExQTJ:L3G+
THP1 NVrIfHVnSW62aXnu[oxidW2jdH;yfUBie3OjeR?= Ml\MNkBpenN? NHTzd2xCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKGi3bXHuJHRJWDFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRVUFvaX7keYNm\CCPQ2CtNUB{\WO{ZYTpc44hcW6ldXLheIVlKG[xcjCyJIhzeyCycnnvdkB1dyCSTVGgZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDFUGlUSSxiSVO1NF0yQC54zszNMi=> M375NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOxNlI4Lz5{NEWzNVIzPzxxYU6=
HEK293 NHXZWYNHfW6ldHnvckBie3OjeR?= NXqwfYtUOTBidV2= MYmyOEBpenN? NIDJUIhVemGwc3HjeIl3[XSrb36gc4YhWFCDUj3nZY1u[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NVXZbmNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVAxQTBpPkK0PFkxODlyPD;hQi=>
HEK293 NX;EdGpWTnWwY4Tpc44h[XO|YYm= NIDmRWkyQCCqcoO= NWPGbZdrSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{BqdmO3YnH0[YQh\m:{IEG4JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4zOc7:TT6= NH7KVHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzN|g2Oyd-MkWzN|M5PTN:L3G+
COS7 M2D2WWZ2dmO2aX;uJIF{e2G7 M2fEfXRz[W6|YXP0bZZifGmxbjDv[kBpfW2jbjDQVGFT\2GvbXGg[ZhxemW|c3XkJIlvKEGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV|ch[2WubIOgbY5kfWKjdHXkJI93\XKwaXfoeEBjgSCmdXHsMYdtdyCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;MD6y{txONg>? NUTDUmNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PVU4PDlpPkK2OVk2PzR7PD;hQi=>
THP1 M{WzS2Z2dmO2aX;uJIF{e2G7 M{Da[VExKHWP NGC0O4czPCCqcoO= MVjVdJJm\3WuYYTpc44hd2ZiQVLDRVEhdVKQQTDlfJBz\XO|aX;uJIlvKGi3bXHuJHRJWDFiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK|IHL5JJFRS1JibXX0bI9lKHKnbHH0bZZmKHSxIHPvcpRzd2x? NIO5ToM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{KyNFA3PSd-MkeyNlAxPjV:L3G+
THP1 MmT5SpVv[3Srb36gZZN{[Xl? M4PXWVExKHWP NFzU[FgzPCCqcoO= NGTwd2ZWeHKnZ4XsZZRqd25ib3[gRWJETzFibWLORUBmgHC{ZYPzbY9vKGmwIHj1cYFvKFSKUEGgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KHGSQ2KgcYV1cG:mIILlcIF1cX[nIITvJINwdnS{b3y= NHHEfIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{KyNFA3PSd-MkeyNlAxPjV:L3G+
COS7 MVXGeY5kfGmxbjDhd5NigQ>? MWW0NkBpenN? MYDUdoFve2GldHn2ZZRqd25ib3[gS2FNPC2odYPl[EBpfW2jbjDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGGodHXyJFQzKGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlXPxE1w NFTpSpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W2NFI5Oid-Mke1OlAzQDJ:L3G+
COS7 NWrEeW5{TnWwY4Tpc44h[XO|YYm= M3\XeFQzKGi{cx?= NUfodIFIXHKjboPhZ5RqfmG2aX;uJIF1KEejbESg[pV{\WRiUGDBVodidW2jIFzCSEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCDZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJIFnfGW{IESyJIhzeyCkeTDseYNq\mW{YYPlJIF{e2G7LDDFR|UxRTBwM{NOwG0v MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV4OUG5OUc,Ojd3NkmxPVU9N2F-
COS7 M2rVUmZ2dmO2aX;uJIF{e2G7 NXzRNWp7PDJiaILz MX;UdoFve2GldHn2ZZRqd25ib3[gS4FtPCCodYPl[EBpfW2jbjDQVGFT\2GvbXGgUGJFKGW6cILld5Nm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGGodHXyJFQzKGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlM5|ryPLh?= NUHiUINwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVg6QTRpPkK3PVE5QTl2PD;hQi=>
PC3 M1\xXmZ2dmO2aX;uJIF{e2G7 Mo\SOVAhfU1? MoHlNlQhcHK| MlPwTY5kemWjc3WgbY4heDJzKGfBSlEqKHC{b4TlbY4h\XiycnXzd4lwdiCrbjDoeY1idiCSQ{OgZ4VtdHNiYYSgOVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M33UU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{m1NlIxLz5{OEO5OVIzODxxYU6=
MDA-MB-231 Ml;sSpVv[3Srb36gZZN{[Xl? NYHndG13PTBidV2= NFfMeFIzPCCqcoO= Mn[xTY5kemWjc3WgbY4heDJzKGfBSlEqKHC{b4TlbY4h\XiycnXzd4lwdiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG2IEWwJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? M{DYRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{m1NlIxLz5{OEO5OVIzODxxYU6=
HEK293 MXzGeY5kfGmxbjDhd5NigQ>? MVGyOEBpenN? NFGyVXpVemGwc3HjeIl3[XSrb36gZYN1cX[rdImgZZQhT2GuNDDmeZNm\CCodXzsJIxmdme2aDDoeY1idiCSUFHS[4FudWFiTFLEJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2xMlHPxE1w NEfKW4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES2OVA6QSd-Mki0OlUxQTl:L3G+
HEK293 M13nSGZ2dmO2aX;uJIF{e2G7 NInQU2Q1KGi{cx?= MXTUdoFve3KncILld5Nqd25iYXP0bZZqfHliYYSgbJVu[W5iUGDBVodidW2jIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCWTl\hcJBp[SCrbnT1Z4VlKE6ILXvhdJBiSiCycn;tc5RmeiCjY4Tpeol1gSCycnX0doVifGWmIH\vdkA1KGi{czDmc4xtd3enZDDifUBVVk[jbIDoZUB{fGmvdXzheIlwdiCjZoTldkA{KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVA:OjMQvF2u MkjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkWwPVkoRjJ6NE[1NFk6RC:jPh?=
SCC15 MW\DfZRwfG:6aXPpeJkh[XO|YYm= Mn;4OVAhfU1? MU[yOEBpenN? MljMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2NEOTViY3XscJMhfHKjboPm[YN1\WRid3n0bEBRWEGUYXzwbIEhe2mUTlGgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEWwJJVOKGGodHXyJFI1KGi{czDifUBz\XOjeoXybY4hemWmdXP0bY9vKGG|c3H5 MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB|MUC2N{c,OjlyM{GwOlM9N2F-
SCC15 M4LST2N6fG:2b4jpZ4l1gSCjc4PhfS=> MV21NEB2VQ>? MmHiNlQhcHK| MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTR2MyPSClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJHBRSVKkZYThJJNqWk6DIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBifCB3MDD1UUBi\nSncjCyOEBpenNiYomgdoV{[Xq3cnnuJJJm\HWldHnvckBie3OjeR?= MknDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyM{GwOlMoRjJ7MEOxNFY{RC:jPh?=
HepG2 M1nIRWZ2dmO2aX;uJIF{e2G7 NEHwemkzPCCqcoO= NX;TVVlVSWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiaX6gbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMh[WO2aY\heIlwdiCxZjDQVHJGKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JIR2[WxibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuNlTPxE1w MljKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByMEG4OFYoRjNyMECxPFQ3RC:jPh?=
HEK293BENA MnXDSpVv[3Srb36gZZN{[Xl? M3zR[lI1KGi{cx?= NFHXfVZVemGwc3HjeIl3[XSrb36gc4YhT0GOND3meZNm\CCqdX3hckBRWEGUZ3HtcYEhfHKjboPm[YN1\WRiaX6gTGVMOjl|QlXORUBk\WyuczDh[pRmeiB{NDDodpMh[nlic4TlZYR6KGeubz3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9Nk4xPTQQvF2u M2XoWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{WxPVM{Lz5|MEO1NVk{OzxxYU6=
HEK293 M4jmXWZ2dmO2aX;uJIF{e2G7 MmWyNVghcHK| MXTUdoFve2GldHn2ZZRqd25ib3[gbJVu[W5iZoXscEBt\W6pdHigVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZYZ1\XJiMUigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCkYYPl[EBtfW2rbnXzZ4Vv[2ViYYPzZZktKEWFNUC9NE4y|ryPLh?= Ml\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|NkK3N|koRjNyM{[yO|M6RC:jPh?=
293H NXi4V3ZuTnWwY4Tpc44h[XO|YYm= MXixOkBpenN? MkHaWJJidnOjY4TpeoF1cW:wIH;mJGdCVDRvRFLEJIZ2e2WmIHj1cYFvKFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6g[ZhxemW|c3XkJIlvKFWDUz3icIEhUEWOIEK5N2gh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCxOkBpenNiZn;scI94\WRiYomgSnJGXCC|dXLzeJJifGViYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEKgbJJ{KGK7IGTSMWZTTVRiYYPzZZktKEWFNUC9NE4xQTkQvF2u NVjRc|B1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0NlkxQTdpPkOwOFI6ODl5PD;hQi=>
3T3L1 M1zVfmZ2dmO2aX;uJIF{e2G7 NX\hTXRSOTBidV2= NVTaNmZyOjRiaILz MWPB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCvb4Xz[UA{XDOOMTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBCWDFibWLORUBmgHC{ZYPzbY9vKGG2IEGwJJVOKGGodHXyJFI1KGi{czDifUBUYUKUIHfy[YVvKGS7ZTDiZZNm\CCUVD3QR3Ih[W6jbInzbZM> M{LoR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUm0OFMzLz5|MEW5OFQ{OjxxYU6=
3T3L1 NV30dZN3TnWwY4Tpc44h[XO|YYm= NXzRfYM4OTBidV2= M1zkRVI1KGi{cx?= NHewcpZC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDtc5V{\SB|VEPMNUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCFREO2JI1TVkFiZYjwdoV{e2mxbjDheEAyOCC3TTDh[pRmeiB{NDDodpMh[nliU2nCVkBoemWnbjDkfYUh[mG|ZXSgVnQuWEOUIHHuZYx6e2m| NWTS[HNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C1PVQ1OzJpPkOwOVk1PDN{PD;hQi=>
3T3L1 NUfpS3VxTnWwY4Tpc44h[XO|YYm= MYixNEB2VQ>? MkLLNlQhcHK| NXq2dWw5SWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiaX6gcY92e2ViM2SzUFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iR3z1eFQhdVKQQTDlfJBz\XO|aX;uJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDTXWJTKGe{ZXXuJIR6\SCkYYPl[EBTXC2SQ2KgZY5idHm|aYO= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODV7NESzNkc,OzB3OUS0N|I9N2F-
3T3L1 MXHGeY5kfGmxbjDhd5NigQ>? NX65[HBUOTBidV2= NYXCVmJbOjRiaILz MWDB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCvb4Xz[UA{XDOOMTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBi\Gmyb37lZ5RqdiCvUl7BJIV5eHKnc4Ppc44h[XRiMUCgeW0h[W[2ZYKgNlQhcHK|IHL5JHN[SlJiZ4Ll[Y4h\HmnIHLhd4VlKFKWLWDDVkBidmGueYPpdy=> MnvBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OUS0N|IoRjNyNUm0OFMzRC:jPh?=
stem cells NWLTTVR2TnWwY4Tpc44h[XO|YYm= MnLQOUBl[Xm| NFS4eWpKdmS3Y4Tpc44hd2ZiYXTpdI9o\W6nc3nzJIlvKGi3bXHuJIJwdmVibXHydo94NWSncnn2[YQhdWW|ZX7jbJlu[Wxic4TlcUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjZHnwc45m[3SrbjDwdo9lfWO2aX;uJI1m[XO3cnXkJI9vKGSjeTC1JIlvKHC{ZYPlcoNmKG:oIFnEXEBjgSCHTFnTRUwhTUN3ME2wMlM2|ryPLh?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ5Mk[5PEc,OzB4N{K2PVg9N2F-
HEK293T NGL4eI5HfW6ldHnvckBie3OjeR?= NUKyOZJQOThiaILz M2P3WXRz[W6|YXP0bZZifGmxbjDv[kBnfWyuIHzlcod1cCCqdX3hckBRWEGUZ3HtcYEzKGW6cILld5Nm\CCrbjDISWszQTOWIHPlcIx{KGOxLXX4dJJme3OrbnegVHBTTSCjZoTldkAyQCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMkZOwG0v MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ5Nke0NUc,OzB4N{[3OFE9N2F-
HEK293T NUPMOmhkTnWwY4Tpc44h[XO|YYm= NUPpcmlQOThiaILz MVLUdoFve2GldHn2ZZRqd25ib3[gZ4hqdWW{aXOgS4FtPCC7ZXHzeEBFSkRiZoXz[YQuWFCDUnfhcY1iKEyERDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHPvMYV5eHKnc4PpcochWFCURTDh[pRmeiBzODDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuN|XPxE1w NF:xZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|ME[3Olc1OSd-M{C2O|Y4PDF:L3G+
HepG2 NULR[HJrTnWwY4Tpc44h[XO|YYm= MUizNEB2VQ>? NXLlRnlHSmmwZHnu[{Bi\m[rbnn0fUB1dyCQQV[xJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKGi3bXHuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhdWm2b3Poc45lemmjbDDy[ZNxcXKjdHnvckBifCB|MDD1US=> NX\ReIVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C3O|AyPTRpPkOwO|cxOTV2PD;hQi=>
HepG2 NYTtdHBZTnWwY4Tpc44h[XO|YYm= MVezNEB2VQ>? NVvCeYEySmmwZHnu[{Bi\m[rbnn0fUB1dyCQQV[xJIlvKGi3bXHuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhdWm2b3Poc45lemmjbDDy[ZNxcXKjdHnvckBifCB|MDD1US=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODd5MEG1OEc,OzB5N{CxOVQ9N2F-
COS7 MWHGeY5kfGmxbjDhd5NigQ>? M2fMcFM6KGi{cx?= NY\keXdiXHKjboPhZ5RqfmG2aX;uJI9nKEejbESt[pV{\WRiaIXtZY4hWFCDUnfhcY1iKHS{YX7z[oVkfGWmIHnuJGNQWzdiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCyR1HMOU1VUy2yR1yzJIFv\CCyUnXucoltdGFvQ13WJIlv[3WkYYTl[EBnd3JiM{mgbJJ{KGK7IHT1ZYwhdHWlaX\ldoF{\SC{ZYDvdpRmeiCjc4PhfUwhTUN3ME2xMlTPxE1w NVPEOFI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G2OFgyOjVpPkOxOlQ5OTJ3PD;hQi=>
K562 NFu3WFBHfW6ldHnvckBie3OjeR?= MXyxNEB2VQ>? MlzzO|IhcHK| NYPGV|h7UW6mdXP0bY9vKG:oIIPlcpNqfGm8YYTpc44hfG9iaX3heIlvcWJvaX7keYNm\CCleYTveI95cWOrdImgbY4hcW2jdHnubYIuemW|aYP0ZY51KGi3bXHuJGs2PjJvSV3BX5JeKGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDj[YxtKGSnYYToJIF1KDFyIIXNJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kAyKHWPIHntZZRqdmmkIHL5JJBzd3CrZHn1cUBqd2SrZHWvWJJqfG:wLWixNFAh\HmnIHLhd4VlKE[DQ2OgZY5idHm|aYO= M1jIeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNkS4NVI2Lz5|MU[0PFEzPTxxYU6=
In vivo

Pioglitazone administered orally (0.3-3 mg/kg/d for 7 days) dose dependently reduces hyperglycemia, hyperlipidemia, and hyperinsulinemia in male fatty rats. Pioglitazone improves glucose tolerance and augmentes the glycemic response to exogenous insulin and clearance of plasma triglyceride in rats. [2] Pioglitazone-treated transgenic mice reveals improved muscle strength and body weight, exhibits a delayed disease onset, and survives significantly longer than nontreated SOD1-G93A mice. [3] Pioglitazone markedly decreases hyperglycemia, hyperlipidemia, hyperinsulinemia, and glucoseintolerance characterized as insulin resistant states in these rats and mice. Pioglitazone potentiates insulin-mediated glucose metabolism in the diaphragm and adipose tissues of yellow KK mice and enhanced the glycemic response to exogenous insulin in Zucker fatty rats. [4] Pioglitazone results in a reduction in the number of activated microglia and reactive astrocytes in the hippocampus and cortex of APPV717I transgenic mice. Pioglitazone decreases beta-secretase-1 (BACE1) mRNA and protein levels in APPV717I transgenic mice. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 79 mg/mL
(201.06 mM)
Ethanol 4 mg/mL
(10.18 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 392.9
Formula

C19H20N2O3S.HCl

CAS No. 112529-15-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04501406 Recruiting Drug: Pioglitazone|Other: Placebo Type 2 Diabetes Mellitus (T2DM)|Nonalcoholic Steatohepatitis University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) December 15 2020 Phase 2
NCT04535700 Recruiting Drug: Pioglitazone 30 mg|Other: standard of care Type 2 Diabetes Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal September 18 2020 Phase 4
NCT00904046 Recruiting Drug: Pioglitazone|Drug: Placebo Uric Acid Kidney Stone Disease University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America Inc. September 5 2019 Not Applicable
NCT04671056 Completed Drug: MGL-3196|Drug: Pioglitazone 15mg Healthy Madrigal Pharmaceuticals Inc. November 9 2018 Phase 1
NCT03501277 Completed Drug: Alogliptin|Drug: Pioglitazone|Drug: SYR-322-4833 BL Healthy Volunteers Takeda May 26 2018 Phase 1
NCT03471117 Recruiting Drug: Pioglitazone|Other: Placebo Chronic Kidney Diseases The University of Texas at Arlington|University of Texas Southwestern Medical Center at Dallas April 1 2018 Phase 4

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Pioglitazone HCl | Pioglitazone HCl supplier | purchase Pioglitazone HCl | Pioglitazone HCl cost | Pioglitazone HCl manufacturer | order Pioglitazone HCl | Pioglitazone HCl distributor